Aspira Women’s Health (NASDAQ:AWH) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research note released on Sunday morning. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners decreased their price target on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

Aspira Women’s Health Stock Up 2.0 %

AWH opened at $0.87 on Friday. Aspira Women’s Health has a 12-month low of $0.74 and a 12-month high of $6.01. The business has a 50 day moving average of $0.91 and a 200-day moving average of $1.73. The stock has a market cap of $13.97 million, a price-to-earnings ratio of -0.60 and a beta of 1.47.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million for the quarter, compared to analyst estimates of $2.60 million. During the same period in the prior year, the business earned ($0.28) EPS. As a group, analysts expect that Aspira Women’s Health will post -1.26 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned about 1.90% of Aspira Women’s Health worth $352,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.